We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Device Detects Brain Tumors Using Urine

By LabMedica International staff writers
Posted on 06 Feb 2023

There has recently been an improvement in cancer survival rates due to early detection of the disease, although the survival rate for brain tumors has remained almost the same for the last 20 years, partly due to their late detection. More...

Brain tumors are often discovered only after the onset of neurological symptoms, such as loss of movement or speech, by when the tumor achieves a considerable size. Detecting the tumor when it is still small and commencing treatment as soon as possible can help save lives. Now, researchers have used a new device to identify a key membrane protein in urine that indicates whether a person has a brain tumor. By using the protein to detect brain cancer, it will be possible to avoid invasive tests and increase the chances of the tumor being detected at an early enough stage for surgery. The finding could also have potential implications for detecting other types of cancer.

The presence of tumor-related extracellular vesicles (EVs) in urine can indicate that a person has a brain tumor. EVs are nano-sized vesicles that perform various functions, including cell-to-cell communication. The EVs found in brain cancer patients have specific types of RNA and membrane proteins, allowing them to be used for detecting the presence of cancer and its progression. EVs are excreted far from the brain, but many EVs from cancer cells still exist stably and are excreted in the urine without breaking down.

Researchers at Nagoya University (Nagoya, Japan) have developed a new analysis platform for brain tumor EVs using nanowires at the bottom of a well plate. They used the device to identify two specific types of EV membrane proteins, known as CD31/CD63, from the urine samples of brain tumor patients. By looking for these tell-tale proteins, doctors can identify tumor patients before they develop symptoms. Additionally, urine testing offers several advantages and is an effective, simple, and non-invasive method because urine contains many informative biomolecules that can be traced back to identify the disease.

“Currently, EV isolation and detection methods require more than two instruments and an assay to isolate and then detect EVs,” said Associate Professor Takao Yasui of Nagoya University Graduate School of Engineering. “The all-in-one nanowire assay can isolate and detect EVs using one simple procedure. In the future, users can run samples through our assay and change the detection part, by selectively modifying it to detect specific membrane proteins or miRNAs inside EVs to detect other types of cancer. Using this platform, we expect to advance the analysis of the expression levels of specific membrane proteins in patients’ urinary EVs, which will enable the early detection of different types of cancer.”

Related Links:
Nagoya University 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.